| Variant | Gene | Type | COSMIC ID | DNA Change (Coding Nucleotide) | Exon |
|---|---|---|---|---|---|
| CDKN2B copy number loss | CDKN2B | CNV | |||
| CDKN2B copy number gain | CDKN2B | CNV | |||
| CDKN2B any mutation | CDKN2B | any |
Interpretations
The CDKN2B gene locus is altered in up to approximately 55% of glioblastoma, most commonly as a homozygous deletion, and frequently with concurrent deletion of the CDKN2A locus. CDKN2A/CDKN2B loss may be associated with increased sensitivity to CDK4/6 inhibitors. The efficacy and toxicity profiles of these inhibitors in the context of a variety of cancer types are currently under evaluation in clinical trials.
The CDKN2B gene locus is altered in up to approximately 60% of bladder cancer, most commonly as a homozygous deletion, and frequently with concurrent deletion of the CDKN2A locus. CDKN2A/CDKN2B loss may be associated with increased sensitivity to CDK4/6 inhibitors. The efficacy and toxicity profiles of these inhibitors in the context of a variety of cancer types are currently under evaluation in clinical trials.
This gene is a known cancer gene.
This gene is a known cancer gene.